POLR2J4 and glioma: Among the six prognostic LCRlncRNAs identified by our risk model, POLR2J4 was selected for functional validation due to its strong association with poor prognosis, high expression in glioma tissues and cell lines, and robust correlation with immune checkpoint activation and chemoresistance-related signatures.